Independent, evidence-based peptide science intelligence. Our editorial team combines expertise in peptide chemistry, molecular pharmacology, and biotech industry analysis.
Most peptides never reach the living layers of your skin. Here is the science of why, and how delivery technologies like palmitoylation, liposomes, and cell-penetrating peptides solve this fundamental problem.
Signal peptides like Matrixyl mimic your skin's natural repair language. Here is what 30 years of biochemistry and clinical research reveals about how they work.
Argireline is called Botox in a bottle. But the science is more nuanced. Here is what the data actually shows about this peptide and what experienced formulators know.
The FDA will hold an advisory committee meeting in July 2026 to review 7 peptides for compounding pharmacy use, while removing 12 from the restrictive Category 2 bulks list. The move follows direct pressure from Health Secretary RFK Jr. and the MAHA movement, marking the most significant peptide regulatory shift in a decade.
Vedana Therapeutics emerges from stealth with $46M Series A to develop anti-PACAP antibody therapies for migraine prevention. Led by the veterans who built the CGRP drug class, the startup targets a neuropeptide pathway that could help the 50%+ of patients who don't respond to current treatments.
Matrixyl sends a fake distress signal to fibroblasts using a five-amino-acid collagen fragment called KTTKS. Here is the full molecular mechanism, clinical data, and what formulators get wrong about concentration and delivery.
Clean skincare brand Mad Hippie launches the Wrinkle Relaxing Eye Treatment ($34.99) — five peptide complexes including Syn-Ake, Argireline Amplified and Matrixyl Synthe'6 in a retinol- and Botox-free eye cream.
